Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat ...

The TL1a inhibitor duvakitug was effective at 14 weeks in patients who had previous exposure to conventional and advanced ...

Artificial intelligence (AI) and "protein language" models can speed the design of monoclonal antibodies that prevent or ...

A rapid multidisciplinary approach is needed to reduce serum free light chain levels and restore kidney function ...

PEMGARDA® (pemivibart) net product revenue of $13.1 million reported for Q3 2025, representing 41% growth year-over-year and 11% growth ...

Drugmaker Bristol-Myers Squibb Co (BMY.N) will globally develop, make and sell a therapy being tested by New York's ...

The U.S. Food and Drug Administration on Friday approved Roche's under-the-skin injection to treat patients with multiple ...

In contrast, the experts noted that several recent FDA approvals introduced first-in-class therapies to the oncology landscape. 1 Among these are menin inhibitors, which block the interaction between ...

Primary nephrotic syndrome in adults, including minimal-change nephrotic syndrome, has an incidence of roughly 0.2 to 0.8 per ...

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance ...

Systemic lupus erythematosus is a lifelong condition that can cause irreversible damage to the major organs in the body, leading to life-threatening complications. These pivotal results are ...

News involving the treatment of multiple myeloma this year was highlighted by talk of a potential cure with a single infusion ...